GlassScriptPhysician profile
Lisa Armao
NPI 1558350066
$79,016.74
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,949 · 2022: $14K · 2023: $24K · 2024: $19K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $9,204 · Food and Beverage: $3,783 · Consulting Fee: $1,545 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,370.50 |
| Travel and Lodging | $9,204.49 |
| Food and Beverage | $3,782.98 |
| Consulting Fee | $1,545.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76,063.63 | 2021-2025 | Jemperli, Zejula |
| Abbvie INC. | $1,531.43 | 2021-2024 | |
| Immunogen, INC. | $521.38 | 2023 | Elahere |
| Astrazeneca Pharmaceuticals LP | $345.02 | 2021-2023 | Lynparza |
| Astellas Pharma US INC | $124.99 | 2024 | Veozah |
| Seagen INC. | $99.95 | 2022 | |
| Aadi Bioscience, INC. | $99.00 | 2023 | Fyarro |
| Celltrion USA INC. | $66.12 | 2023 | Vegzelma |
| Merck Sharp & Dohme LLC | $62.23 | 2025 | Lynparza |
| Sumitomo Pharma America, INC. | $24.17 | 2025 | Gemtesa |
| Lilly USA, LLC | $23.66 | 2024 | Zepbound, Mounjaro |
| Janssen Biotech, INC. | $23.14 | 2024 | Akeega, Balversa, Erleada |
| Pfizer INC. | $18.67 | 2021 | |
| Genmab U.S., INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Armao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.